PDL BioPharma — Q3 2017 Earnings Presentation
15 slides from PDL BioPharma's earnings presentation, Nov 2, 2017
Slide 1: Third Quarter 2017 Financial Results Conference Call
PDL Third Quarter 2017 Financial Results Conference Call November 2, 2017
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains forward-looking statements, including PDL's expectations with respectto its future royalty revenues, expenses, net income, and cash provided by operating activities. Each of these forward-looking statements involves risks and uncertainties. Actua
Slide 3: Building Value Through Investments
Building Value Through Investments o Focused on growth in order to continue value creation for shareholders. o Strong financial position enables us to continue to seek high quality acquisition candidates. Pleased with caliber of investment opportunities. » Finished third quarter with over $500 milli
Slide 4: Noden Background
Noden Background o Noden Pharma = Platform upon which to build a specialty pharmaceutical company. = PDL now owns 100% of Noden companies. = Noden already has two products on the market—both indicated for hypertension. —Tekturna and Tekturna HCT, as they are known in the US, and Rasilez® and Rasilez
Slide 5: Building Profitable Growth in US
Building Profitable Growth in US o Reported revenues on the Noden products for Q317 of $15.1 million. o In the process of turning the trajectory toward profitable growth. o Noden products have not been adequately marketed for several years. o Very capable sales team of 65 people now in place. o Refi
Slide 6: Messages from the Sales Team
Messages from the Sales Team o Hypertension is a generic market with a large unmet need but very little promotional activity. It is exactly the kind of market where a relatively small commercial team, promoting a product that addresses a significant part of that unmet need, can have an impact. o Alm
Slide 7: Maximizing Profitability— Ex US
Maximizing Profitability— Ex US o On track in transferring marketing authorizations for Rasilez to our country distributors and starting to book sales. = Expect the transfers to be complete in most markets by year end, with some Asian markets being completed in early 2018. o Assessing each country o
Slide 8: Dominique Monnet, President
Dominique Monnet, President o PDL appointed Dominique Monnet to position of president. o Brought over 30 years international biotech/pharma business experience. o Will work closely with Noden’s leadership and on future PDL acquisitions. o Believe his proven track record of achieving commercial succe
Slide 9: Neos Therapeutics
PDL Neos Therapeutics
Slide 10: Royalty & Debt Investments
16 Royalty & Debt Investments Royalty Transaction, ‘Senior Secured Financing Wellstat Diagnostics, LUC we $44,000,000 November2012 Royalty Acquisition 3% Depomed 240,500,000 October 2013, Financing A | LENSAR $60,000,000 October 2013, ‘Senior Secured inaneing Oo DURATA $70,000,000 October 2013, Roya
Slide 11: PDL Sells kaleo Asset
"1 PDL Sells kaleo Asset o Entered into agreement on September 21, 2017 with third party purchaser. o Sold entire interest in kaleo note. o The purchaser paid PDL an amount equal to 100% plus a premium of approximately 1% for the aggregate purchase price of $141.7 million. « This is subject to an 18
Slide 12: Settlement with Valeant
Settlement with Valeant o On October 27", we and Depomed entered into a settlement agreement with Valeant Pharmaceuticals International, Inc. o Agreement resolves all matters addressed in Depomed lawsuit of September 7, 2017 relating to underpayment of royalties by Valeant. o Litigation is dismissed
Slide 13: Third Quarter 2017 Financials
Third Quarter 2017 Financials Three Months Ended Nine Months Ended September 30, September 30, (In thousands, except per share amounts) (unaudited) 2017 2016 2017 2016 Royaties from Queen et al. patents $1443 _§ 14.958 _S 31,884 _§ 150,645 Royalty rights - change in fair value 35,353 16.085 132.224
Slide 14: Third Quarter 2017 Financials
Third Quarter 2017 Financials Condensed consolidated balance sheet (unaudited) September 30, December 31, 2017 2016 Cash, cash equivalents and investments $ 516,494 $ 242,141 Total notes receivable $ 70,636 $ 270,950 Total royalty rights - at fair value $ 351,969 $ 402,318 Total assets $ 1,223,838 $
Slide 15: Question and Answer Session
PDL Question and Answer Session